Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.

ABSTRACT:

Objectives

Nicotine metabolism rates differ considerably among individuals, even after controlling for variation in the major nicotine-metabolizing enzyme, CYP2A6. In this study, the impact of genetic variation in alternative metabolic enzymes and transporters on nicotine and cotinine (COT) pharmacokinetics and smoking was investigated.

Methods

We examined the impact of UGT2B10, UGT2B17, FMO3, NAT1, and OCT2 variation on pharmacokinetics and smoking (total nicotine equivalents and topography) before and after stratifying by CYP2A6 genotype in 60 African American (AA) smokers who received a simultaneous intravenous infusion of deuterium-labeled nicotine and COT.

Results

Variants in UGT2B10 and UGT2B17 were associated with urinary glucuronidation ratios (glucuronide/fre

SUBMITTER: Taghavi T 

PROVIDER: S-EPMC5346034 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature